GenrAb is awarded the North Texas Therapeutics Innovator of the Year for 2023

GenrAb was awarded the 2023 North Texas Therapeutics Innovator of the Year award by Lyda Hill at the annual Innovation Days Conference sponsored by The University of Texas Southwestern, LaunchBio and JP Morgan. Dr. Benjamin Greenberg presented the innovative technology behind the formation of GenrAb as well as preclinical results for the Company’s lead antibody therapy. Dr. Greenberg described how the team at GenrAb identified well over 250 potentially therapeutic antibodies using its Antibody Gene Signature (AGS) and then chose TGM-010 for its demonstrated ability to bind to both human and mouse neurons, its neuroprotective capabilities through in-vitro assays of neuronal stress and its ability to reduce disability in well-established preclinical models of neurodegeneration. There was stiff competition from other great Texas biotechs, but GenrAb was voted as the most innovative and promising Company.